

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

NCT06445322

Status RECRUITING
Sponsor Ascidian Therapeutics, Inc
Enrollment 50 participants

Key Eligibility Criteria

Inclusion (2)

- Presence of mutations in the ABCA4 gene
- ABCA4 retinopathy phenotype (Stargardt disease type 1 or cone-rod dystrophy)

Exclusion (3)

- The presence of pathogenic or likely pathogenic mutations in other genes known to cause cone-rod dystrophy or Stargardt maculopathy
- Retinal disease other than ABCA4-related retinopathy
- Presence of a medical condition (systemic or ophthalmic), psychiatric condition, including substance abuse disorder, or physical examination or laboratory finding that may in the opinion of the principal investigator and sponsor preclude adherence to the scheduled study visits, safe participation in the study, or affect the results of the study.

Locations (8 total)

University of San Francisco, San Francisco, California, United States
Vitreo Retinal Associates, Gainesville, Florida, United States
Wilmer Eye Institute at Johns Hopkins, Baltimore, Maryland, United States
... and 5 more locations

<https://clinicaltrials.gov/study/NCT06445322>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.